Australia's most trusted
source of pharma news
Friday, 21 November 2025
Posted 21 November 2025 AM
BMS has reported impressive results for a combination of Opdivo and Yervoy in treating a number of rare cancers, precisely the situation its recent multicancer approval is intended to facilitate.
The Phase 2 MoST-CIRCUIT trial was conducted across 17 hospitals in Australia and New Zealand, and was the first in the world to test whether combining two immunotherapies can enhance treatment response in non-colorectal dMMR/MSI-H cancers.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.